Journal of the Formosan Medical Association (Feb 2018)

Preimplantation genetic diagnosis and screening: Current status and future challenges

  • Hsin-Fu Chen,
  • Shee-Uan Chen,
  • Gwo-Chin Ma,
  • Sung-Tsang Hsieh,
  • Horng-Der Tsai,
  • Yu-Shih Yang,
  • Ming Chen

DOI
https://doi.org/10.1016/j.jfma.2017.08.006
Journal volume & issue
Vol. 117, no. 2
pp. 94 – 100

Abstract

Read online

Preimplantation genetic diagnosis (PGD) is a clinically feasible technology to prevent the transmission of monogenic inherited disorders in families afflicted the diseases to the future offsprings. The major technical hurdle is it does not have a general formula for all mutations, thus different gene locus needs individualized, customized design to make the diagnosis accurate enough to be applied on PGD, in which the quantity of DNA is scarce, whereas timely result is sometimes requested if fresh embryo transfer is desired. On the other hand, preimplantation genetic screening (PGS) screens embryo with aneuploidy and was also known as PGD-A (A denotes aneuploidy) in order to enhance the implantation rates as well as livebirth rates. In contrasts to PGD, PGS is still under ferocious debate, especially recent reports found that euploid babies were born after transferring the aneuploid embryos diagnosed by PGS back to the womb and only very few randomized trials of PGS are available in the literature. We have been doing PGD and/or PGS for more than 10 years as one of the core PGD/PGS laboratories in Taiwan. Here we provide a concise review of PGD/PGS regarding its current status, both domestically and globally, as well as its future challenges.

Keywords